SNMMI: AI May Enhance Detection and Risk Assessment for Multiple Cancers on Whole-Body PET/CT Scans
Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.
The use of artificial intelligence (AI)-powered tumor segmentation on whole-body positron emission tomography/computed tomography (PET/CT) scans yielded median true positive rates (TPRs) of 75 percent, 85 percent, 87 percent, and 75 percent, respectively, for lung cancer, melanoma, lymphoma, and prostate cancer, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
For the study, researchers developed a deep transfer learning model in order to facilitate automated tumor segmentation on whole-body PET/CT scans. The model was trained on 611 FDG PET/CT scans from patients with a variety of lung cancers including head and neck cancer, lymphoma, lung cancer, breast cancer and melanoma, according to the study. The study authors noted the model training also included 408 PET/CT scans from patients with prostate cancer.
Here one can see illustrated examples of tumor segmentation predictions reflecting the reported capability of an emerging deep learning model to detect and facilitate risk stratification for a variety of cancers including lung, prostate, and breast cancer. (Images courtesy of SNMMI.)
“Most AI models that aim to detect cancer are built on small to moderately sized datasets that usually encompass a single malignancy and/or radiotracer,” noted Kevin H. Leung, M.D., a research associate at Johns Hopkins University School of Medicine. “This represents a critical bottleneck in the current training and evaluation paradigm for AI applications in medical imaging and radiology.”
In addition to the aforementioned TPR data, the researchers noted that the deep transfer learning model had median positive predictive values (PPVs) of 92 percent for lung cancer, 76 percent for melanoma, 87 percent for lymphoma, and 76 percent for prostate cancer.
The deep transfer learning model also predicted prostate cancer with an 83 percent accuracy rate and an 86 percent area under the receiver operating characteristic curve (AUROC), according to the researchers. They pointed out that the model’s classification of these patients with low, intermediate, and high risk correlated with mean follow-up prostate-specific antigen (PSA) levels of 9.18, 26.92 and 727.46 ng/ml respectively.
“In addition to performing cancer prognosis, the (deep transfer learning) approach provides a framework that will help improve patient outcomes and survival by identifying robust predictive biomarkers, characterizing tumor subtypes, and enabling the early detection and treatment of cancer,” emphasized Leung. “The approach may also assist in the early management of patients with advanced, end-stage disease by identifying appropriate treatment regimens and predicting response to therapies, such as radiopharmaceutical therapy.”
Reference
1. Leung K, Rowe SP, Sadaghiani MS, et al. Fully automated whole-body tumor segmentation on PET/CT using deep transfer learning. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 10, 2024.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
